Thrombosis in multiple myeloma: mechanisms, risk assessment and management

Osnat Jarchowsky, Orly Avnery, Martin H. Ellis*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Multiple myeloma (MM) is associated with an increased risk of venous and arterial thrombosis. Pathophysiologic mechanisms include patient, disease and treatment related factors. Risk assessment models have been developed to determine whichpatients are at highest thrombotic risk and pursuant to this, risk adapted thrombosis prophylaxis has been suggested. Areas in which further basic and clinical research is imperative include the molecular and cellular mechanisms of thrombosis in myeloma, the inclusion of relevant biomarkers in risk assessment scores and controlled clinical trials of VTE prophylaxis and treatment using direct oral anticoagulants.

Original languageEnglish
Pages (from-to)1905-1913
Number of pages9
JournalLeukemia and Lymphoma
Issue number12
StatePublished - 2023


  • Venous thromboembolism
  • arterial thrombosis
  • prophylaxis
  • risk assessment


Dive into the research topics of 'Thrombosis in multiple myeloma: mechanisms, risk assessment and management'. Together they form a unique fingerprint.

Cite this